Russell Investments Group Ltd. Buys 7,407 Shares of Cryoport, Inc. (NASDAQ:CYRX)

Russell Investments Group Ltd. raised its stake in Cryoport, Inc. (NASDAQ:CYRX) by 135.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 12,875 shares of the company’s stock after purchasing an additional 7,407 shares during the period. Russell Investments Group Ltd.’s holdings in Cryoport were worth $100,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Wells Fargo & Company MN lifted its holdings in shares of Cryoport by 29.4% in the 4th quarter. Wells Fargo & Company MN now owns 28,767 shares of the company’s stock worth $224,000 after purchasing an additional 6,533 shares in the last quarter. Trexquant Investment LP raised its holdings in Cryoport by 11.8% during the fourth quarter. Trexquant Investment LP now owns 239,138 shares of the company’s stock worth $1,860,000 after buying an additional 25,260 shares during the last quarter. Franklin Resources Inc. lifted its stake in shares of Cryoport by 0.4% in the fourth quarter. Franklin Resources Inc. now owns 387,131 shares of the company’s stock valued at $3,012,000 after buying an additional 1,512 shares in the last quarter. Okabena Investment Services Inc. acquired a new position in shares of Cryoport during the fourth quarter valued at about $615,000. Finally, Norges Bank bought a new stake in shares of Cryoport during the fourth quarter worth about $2,711,000. Institutional investors and hedge funds own 92.90% of the company’s stock.

Insider Transactions at Cryoport

In other Cryoport news, CEO Jerrell Shelton sold 4,620 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $6.29, for a total transaction of $29,059.80. Following the completion of the transaction, the chief executive officer now directly owns 765,399 shares of the company’s stock, valued at approximately $4,814,359.71. This represents a 0.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 19,830 shares of company stock worth $118,353 in the last quarter. Insiders own 10.10% of the company’s stock.

Wall Street Analysts Forecast Growth

CYRX has been the topic of several recent research reports. Guggenheim reaffirmed a “buy” rating and issued a $10.00 price target on shares of Cryoport in a research report on Wednesday, April 16th. UBS Group lifted their target price on Cryoport from $10.00 to $11.00 and gave the company a “buy” rating in a research report on Tuesday, April 1st. Roth Mkm reissued a “buy” rating and issued a $15.00 price target on shares of Cryoport in a research report on Tuesday, April 1st. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price objective on shares of Cryoport in a report on Wednesday, April 16th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Cryoport presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.67.

Cryoport Stock Down 2.2 %

CYRX stock opened at $5.76 on Friday. The stock has a market cap of $287.48 million, a P/E ratio of -1.70 and a beta of 1.81. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48. The stock’s fifty day simple moving average is $5.88 and its two-hundred day simple moving average is $6.95. Cryoport, Inc. has a 1-year low of $4.58 and a 1-year high of $17.41.

Cryoport (NASDAQ:CYRX) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.09). The company had revenue of $59.53 million for the quarter, compared to the consensus estimate of $58.71 million. Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. During the same quarter in the previous year, the company posted ($0.29) EPS. Analysts expect that Cryoport, Inc. will post -0.99 EPS for the current year.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.